Free Trial

HUTCHMED (HCM) Competitors

HUTCHMED logo
$14.31 -0.30 (-2.05%)
(As of 12/20/2024 05:31 PM ET)

HCM vs. QGEN, ITCI, ROIV, ASND, RVMD, LNTH, LEGN, NUVL, BPMC, and ELAN

Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Nuvalent (NUVL), Blueprint Medicines (BPMC), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

HUTCHMED vs.

HUTCHMED (NASDAQ:HCM) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings.

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Qiagen has a net margin of 4.73% compared to HUTCHMED's net margin of 0.00%. Qiagen's return on equity of 13.43% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMEDN/A N/A N/A
Qiagen 4.73%13.43%8.10%

HUTCHMED presently has a consensus price target of $19.00, suggesting a potential upside of 32.77%. Qiagen has a consensus price target of $51.88, suggesting a potential upside of 16.13%. Given HUTCHMED's higher possible upside, equities analysts plainly believe HUTCHMED is more favorable than Qiagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Qiagen
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67

HUTCHMED received 66 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 66.32% of users gave HUTCHMED an outperform vote while only 60.88% of users gave Qiagen an outperform vote.

CompanyUnderperformOutperform
HUTCHMEDOutperform Votes
315
66.32%
Underperform Votes
160
33.68%
QiagenOutperform Votes
249
60.88%
Underperform Votes
160
39.12%

HUTCHMED has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Qiagen has higher revenue and earnings than HUTCHMED.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED$420.26M5.94$100.78MN/AN/A
Qiagen$1.97B5.18$341.30M$0.39114.54

In the previous week, Qiagen had 5 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Qiagen and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.05 beat Qiagen's score of 0.47 indicating that HUTCHMED is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HUTCHMED
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Qiagen
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Qiagen beats HUTCHMED on 10 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCM vs. The Competition

MetricHUTCHMEDPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.49B$6.57B$5.01B$9.08B
Dividend YieldN/A3.09%4.87%4.21%
P/E RatioN/A10.55135.0717.15
Price / Sales5.94195.041,120.63116.80
Price / Cash26.0357.1640.5837.88
Price / Book3.355.104.754.78
Net Income$100.78M$151.51M$118.50M$225.60M
7 Day Performance-8.15%-2.13%-1.85%-1.21%
1 Month Performance-19.15%-3.13%11.28%3.09%
1 Year Performance-15.72%11.54%29.92%16.48%

HUTCHMED Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCM
HUTCHMED
2.5943 of 5 stars
$14.31
-2.1%
$19.00
+32.8%
-15.0%$2.49B$420.26M0.001,988Positive News
QGEN
Qiagen
3.7415 of 5 stars
$45.43
+0.1%
$51.15
+12.6%
+3.1%$10.37B$1.97B117.035,967
ITCI
Intra-Cellular Therapies
4.0406 of 5 stars
$84.54
+1.8%
$97.23
+15.0%
+27.8%$8.96B$612.78M-95.91560
ROIV
Roivant Sciences
3.0418 of 5 stars
$12.13
+2.4%
$17.93
+47.8%
+16.2%$8.83B$129.13M2.10860Insider Trade
ASND
Ascendis Pharma A/S
3.128 of 5 stars
$136.02
+4.7%
$191.77
+41.0%
+12.6%$8.25B$327.43M-16.52640
RVMD
Revolution Medicines
4.5467 of 5 stars
$44.89
-0.3%
$63.67
+41.8%
+71.5%$7.55B$11.58M-12.54443Insider Trade
LNTH
Lantheus
4.3768 of 5 stars
$94.50
+1.6%
$130.00
+37.6%
+53.4%$6.57B$1.50B15.42834Analyst Forecast
LEGN
Legend Biotech
1.553 of 5 stars
$33.72
-4.0%
$81.54
+141.8%
-43.2%$6.16B$520.18M-36.971,800
NUVL
Nuvalent
2.1736 of 5 stars
$86.63
-0.3%
$112.60
+30.0%
+16.9%$6.16BN/A-25.0340Insider Trade
News Coverage
Positive News
BPMC
Blueprint Medicines
2.5727 of 5 stars
$95.54
+2.5%
$122.11
+27.8%
+7.2%$6.07B$249.38M-44.17640Insider Trade
ELAN
Elanco Animal Health
3.7675 of 5 stars
$12.17
+0.6%
$16.75
+37.6%
-17.0%$6.02B$4.45B30.259,300

Related Companies and Tools


This page (NASDAQ:HCM) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners